Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice?

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 3, 1997, Pages 607-610

  Lounis, Nacer ^a   Ji, Baohong ^a   Truffot Pernot, Chantal ^a   Grosset, Jacques ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ISEPAMICIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; STREPTOMYCIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG POTENCY; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TUBERCULOSIS;

EID: 0031035789     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.3.607     Document Type: Article

References (32)

1. Allen, B. W., D. A. Mitchison, Y. C. Chan, and W. G. L. Allan. 1993. Amikacin in the treatment of pulmonary tuberculosis. Tubercle 64:111-118.
2. Barr, W. H., R. Colucci, E. Radwanski, N. Zampaglione, D. Cutler, C. C. Lin, M. Elliott, and M. B. Affrime. 1995. Pharmacokinetics of isepamicin. J. Chemother. 7(Suppl. 2):53-61.
3. Ben-Dov, I., and G. R. Mason. 1987. Drug-resistant tuberculosis in a Southern California hospital. Trends from 1969 to 1984. Am. Rev. Respir. Dis. 135:1307-1310.
4. Blum, D. 1995. An overview of the safety of isepamicin in adults. J. Chemother. 7(Suppl. 2):87-93.
5. Carbon, C. 1995. Overview of the efficacy of isepamicin in the adult core clinical trial programme. J. Chemother. 7(Suppl. 2):79-85.
6. Chien, S. C., A. T. Chow, C. L. Fowler, R. R. Williams, S. Callery-D'Amico, F. A. Wong, and R. K. Nayak. 1996. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750 mg and 1 g doses of levofloxacin in healthy volunteers, abstr. A14, p. 3. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
7. Culliton, B. J. 1992. Drug-resistant TB may bring epidemic. Nature (London) 356:472.
8. Frieden, T. R., T. Sterling, A. Pablos-Mendez, J. O. Kilburn, G. M. Cautben, and S. W. Dooley. 1993. The emergence of drug-resistant tuberculosis in New York City. N. Engl. J. Med. 328:521-526.
9. Goble, M., M. D. Iseman, L. A. Madsen, D. Waite, L. Ackerson, and C. R. Horsburgh. 1993. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N. Engl. J. Med. 328:527-532.
10. Godfrey, K. 1985. Statistics in practice. Comparing the means of several groups. N. Engl. J. Med. 313:1450-1456.
11. Grosset, J., C. Truffot-Pernot, J. Fermanian, and H. Lecoeur. 1982. Activité stérilisante des différents antibiotiques dans la tuberculose expérimentale de la souris. Pathol. Biol. 30:444-448.
12. Grosset, J. H. 1989. Present status of chemotherapy for tuberculosis. Rev. Infect. Dis. 11:5347-5352.
13. Grumbach, F. 1965. Etudes chimiothérapiques sur la tuberculose avancée de la souris. Adv. Tuberc. Res. 14:31-96.
14. Grumbach, F. 1969. Experimental 'in vivo' studies of new antituberculosis drugs: caprcomycin, ethambutol, rifampicin. Tubercle 50(Suppl.):12-21.
15. Hirano, K., Y. Kazumi, C. Abe, T. Mori, M. Aoki, and T. Aoyagi. 1996. Resistance to antituberculosis drugs in Japan. Tubercle Lung Dis. 77:130-135.
16. Hoeprich, P. D. 1994. Antibacterial chemotherapy, p. 247-274. In P. D. Hoeprich, M. C. Jordan, and A. R. Ronald (ed.), Infectious diseases, 5th ed. J. B. Lippincott Company, Philadelphia, Pa.
17. Ji, B., C. Truffot-Pernot, and J. Grosset. 1991. In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis. Tubercle 72: 181-186.
18. Ji, B., E. G. Perani, C. Petinom, L. N'Deli, and J. H. Grosset. 1994. Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy. Antimicrob. Agents Chemother. 38:662-667.
19. Ji, B., N. Lounis, C. Truffot-Pernot, and J. Grosset. 1995. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 39:1341-1344.
20. Jones, R. N. 1995. Isepamicin (SCH 21420, i-N-HAPA gentamicin B): microbiological characteristics including antimicrobial potency and spectrum of activity. J. Chemother. 7(Suppl. 2):7-16.
21. Lalande, V., C. Truffot-Perenot, A. Paccaly-Moulin, J. Grosset, and B. Ji. 1993. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob. Agents Chemother. 37:407-413.
22. Medical Research Council Investigation. 1948. Streptomycin treatment of pulmonary tuberculosis. Br. Med. J. 2:769-782.
23. Medical Research Council Investigation. 1950. Treatment of pulmonary tuberculosis with streptomycin and para-amino-salicylic acid. Br. Med. J. 2:1073-1086.
24. O'Brien, R. J. 1993. The treatment of tuberculosis, p. 207-240. In L. B. Reichman and E. S. Hershfield (ed.), Tuberculosis: a comprehensive international approach. Marcel Dekker, Inc., New York, N.Y.
25. Raleigh, J. W. 1984. Chemotherapy of tuberculosis, p. 1007-1020. In C. P. Kubica and L. G. Wayne (ed.), The mycobacteria: a sourcebook. Marcel Dekker, Inc., New York, N.Y.
26. Sudre, P., H. G. Ten Dam, and A. Kochi. 1992. Tuberculosis: a global overview of the situation today. Bull. W. H. O. 70:149-159.
27. Truffot-Pernot, C., B. Ji, and J. Grosset. 1991. Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments. Tubercle 72:57-64.
28. Tsukamura, M., E. Nakamura, S. Yoshii, and H. Amano. 1985. Therapeutic effect of a new antibacterial substance ofloxacin (DL-8280) on pulmonary tuberculosis. Am. Rev. Respir. Dis. 131:352-356.
29. Turett, G. S., E. E. Telzak, L. V. Torian, S. Blum, D. Alland, I. Weisfuse, and B. A. Fazal. 1995. Improved outcomes for patients with multidrug-resistant tuberculosis. Clin. Infect. Dis. 21:1238-1244.
30. Winer, B. J. 1971. Statistical principles in experimental design, 2nd ed. McGraw-Hill, New York, N.Y.
31. Winn, R. E., and G. C. Prechter. 1994. Pulmonary tuberculosis, p. 447-464. In P. D. Hoeprich, M. C. Jordan, and A. R. Ronald (ed.), Infectious diseases, 5th ed. J. B. Lippincott Company, Philadelphia, Pa.
32. World Health Organization Working Group. 1991. Tuberculosis research and development. WHO/TB/91-162. World Health Organization, Geneva, Switzerland.